stockrowGSK PLC Sponsored ADR
GSK Healthcare Drug Manufacturers General
GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024.
- Revenue
- +3.75%
- EPS
- −14.7%
- Free cash flow
- +62.4%
- Total debt
- +33.2%
Quarter to September 2026, against a year earlier
Follow GSK
Alert me
GSK PLC Sponsored ADR (GSK) Shares outstanding
GSK PLC Sponsored ADR's shares outstanding at the end of fiscal 2025 was $2.1B, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $2.0B. Over the past ten years it has ranged from $2.0B (fiscal 2015) to $2.1B (fiscal 2024); the current reading is higher than 91% of that period. GSK PLC Sponsored ADR ranks 7th of 20 Drug Manufacturers General companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $2.1B | (0.60%) |
| FY2024 | $2.1B | 0.75% |
| FY2023 | $2.1B | 0.66% |
| FY2022 | $2.0B | 2.04% |
| FY2021 | $2.0B | (0.69%) |
| FY2020 | $2.0B | 0.44% |
| FY2019 | $2.0B | 0.91% |
| FY2018 | $2.0B | 0.61% |
| FY2017 | $2.0B | 0.65% |
| FY2016 | $2.0B | 0.43% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $2.0B | 0.27% |
| Jun 2026 | $2.0B | (0.29%) |
| Mar 2026 | $2.0B | (1.04%) |
| Dec 2025 | $2.1B | 0.37% |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| PFE Pfizer Inc. compare | $5.8B |
| NVO Novo Nordisk A/S compare | $4.4B |
| SNY Sanofi compare | $2.4B |
| BMY Bristol Myers Squibb Company compare | $2.1B |
| GSK GSK PLC Sponsored ADR | $2.0B |
| AZN AstraZeneca PLC compare | $1.6B |
| GILD Gilead Sciences, Inc. compare | $1.3B |
| AMGN Amgen Inc. compare | $546.0M |
| BIIB Biogen Inc. compare | $147.8M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on GSK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement